The obesity explosion of recent years has been followed by further development of diabetes and prediabetes, which has reached epidemic proportions in the United States and globally. Type 2 diabetes mellitus (T2DM) is a cardiovascular risk equivalent and is associated with premature cardivascular disease (CVD), hypertension, and dyslipidemia. CVD is the leading cause of death in people with T2DM.
Get full access to this article
View all access options for this article.
References
1.
HandelsmanY, GoldbergRB, GarveyWT, FonsecaVA, RosenstockJ, JonesMR, LaiY-L, JinX, MisirS, NagendranS, AbbySL. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized prospective study. Endocr Pract, 2010; 16:617–628.
2.
RodbardHW, JellingerPS, DavidsonJA, EinhornD, GarberAJ, GrunbergerG, HandelsmanY, HortonES, LebovitzH, LevyP, MoghissiES, SchwartzSS. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract, 2009; 15:540–559.
3.
NathanDM, BuseJB, DavidsonMB. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009; 32:193–203.
4.
GarberAJ, HandelsmanY, EinhornD, BergmanDA, BloomgardenZT, FonsecaV, GarveyTW, GavinJRIII, GrunbergerG, HortonES, JellingerPS, JonesKL, LebovitzH, LevyP, McGuireDK, MoghissiES, NestoRW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract, 2008; 14:933–946.
